Valacyclovir Hydrochloride vs Acyclovir for Anogenital Herpes in HIV-Infected Patients
Valacyclovir hydrochloride
+ Acyclovir
Blood-Borne Infections+32
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This clinical trial is about comparing two medications, valacyclovir hydrochloride (256U87) and acyclovir, to treat recurrent anogenital herpes in HIV-infected patients with CD4 counts equal to or greater than 100 cells/mm3. The goal of this study is to find a safe and effective treatment option for these patients, addressing the need for better care in managing this condition. In this study, participants will receive either valacyclovir hydrochloride (256U87) or acyclovir orally. The study will evaluate the safety and efficacy of these medications by monitoring the frequency and severity of herpes outbreaks, as well as any potential side effects. This information will help determine which medication is more suitable for treating anogenital herpes in HIV-infected patients.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 46 locations
Univ of Arizona / Health Science Ctr
Tucson, United StatesCombat Group
Los Angeles, United StatesLos Angeles County - USC Med Ctr
Los Angeles, United States